We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Partnership Agreement to Provide Funding for Studies on Immunology of Cancer

By LabMedica International staff writers
Posted on 28 Feb 2016

A partnership agreement between a Germany-based pharmaceutical company and a major Israeli research institute will ensure several years' funding for studies in the fields of immunology and immuno-oncology.

The agreement between Merck KGaA (Darmstadt, Germany) and the Weizmann Institute of Science (Rehovot, Israel) confirms the German pharmaceutical company's commitment to the Israeli institute by providing the framework for provision of funds amounting to one million euros per year for each of the next three years. The funds will be used to promote research in the fields of immunology and immuno-oncology over the initial three-year period with an option for multiple successive extensions of two years each.

Merck’s connection to the Weizmann Institute stretches as far back as 1978. Merck’s top selling multiple sclerosis drug Rebif, which had sales of 1.8 billion euros in 2014, has intellectual roots in the Weizmann Institute, as has its oncology drug Erbitux, which had sales of 900 million euros in 2014.

“We have focused our healthcare research activities on the highly promising fields of immuno-oncology, immunology, and oncology as we are striving to deliver new solutions to respond to unmet medical needs,” said Stefan Oschmann, deputy CEO and vice chairman of the executive board of Merck KGaA. “We are excited that the new framework agreement will cover the first two of these three areas and are already looking forward to the proposals of the distinguished Weizmann scientists.”

“We are proud that such a fruitful relationship like the one we have with Merck has now been extended and that we have the chance to take part in creating new innovative solutions in such critical fields that so many patients globally are suffering from,” said Dr. Mudi Sheves, vice president of technology transfer at the Weizmann Institute of Science.

Related Links:
Merck KGaA
Weizmann Institute of Science

Visit expo >

Gold Member

Immunochromatographic Assay

CRYPTO Cassette

POC Helicobacter Pylori Test Kit
Hepy Urease Test

ESR Analyzer

TEST1 2.0

Silver Member

PCR Plates

Diamond Shell PCR Plates

Latest BioResearch News

Channels

Clinical Chemistry

view channel

Blood Test Could Predict and Identify Early Relapses in Myeloma Patients

Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more

Image: The sensitive Raman imaging system can detect very faint signals from SERS nanoparticles that bind to tumor markers (Photo courtesy of Zhen Qiu/Michigan State University)

Compact Raman Imaging System Detects Subtle Tumor Signals

Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more

Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics

People with diabetes often need to measure their blood glucose multiple times a day, most commonly through finger-prick blood tests or implanted sensors. These methods can be painful, inconvenient, and... Read more

POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens

Pseudomonas aeruginosa is a major cause of hospital-acquired and ventilator-associated pneumonia, particularly in lung transplant recipients and patients with structural lung disease. Its ability to form... Read more

Molecular Diagnostics

view channel

Multiplex Antibody Assay Could Transform Hepatitis B Immunity Testing

Hepatitis B remains a major global health challenge, yet immunity testing has historically been constrained by cost, operational complexity, and single-analyte approaches. Now, a multiplex antibody assay... Read more

Genetic Testing Improves Comprehensive Risk-Based Screening for Breast Cancer

Breast cancer screening has long relied on age-based guidelines, assuming similar risk across all women despite clear evidence that individual risk varies widely. This one-size-fits-all approach can lead... Read more

Urine Test Could Reveal Real Age and Life Span

Chronological age does not always reflect how quickly the body is aging, as biological age is shaped by genetics, stress, sleep, nutrition, and lifestyle factors such as smoking. A higher biological age... Read more

Genomic Test Identifies African Americans at Risk for Early Prostate Cancer Recurrence

Prostate cancer is one of the most commonly diagnosed cancers in men and a leading cause of cancer-related death, particularly in the United States. African American men face a disproportionately higher... Read more

Hematology

view channel

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Image: Sickle cell disease patients with higher levels of RMVs, AMVs, and EMVs were found to have more severe disease (Photo courtesy of Adobe Stock)

Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients

Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Immunology

view channel

Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response

Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more

Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs

Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more

Blood Test Could Detect Adverse Immunotherapy Effects

Immune checkpoint inhibitors have transformed cancer treatment, but they can also trigger serious immune-related adverse events that damage healthy organs and may become life-threatening if not detected early.... Read more

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Microbiology

view channel

Image: Test strips with various uropathogenic bacterial species that are responsible for the majority of urinary tract infections (Photo courtesy of Henning Sabersky-Müssigbrodt/TUM)

New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier

Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more

Image: A digital tree built from DNA-like connections represents how scientists trace the ancestry of microbes

Breakthroughs in Microbial Analysis to Enhance Disease Prediction

Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more

Blood-Based Diagnostic Method Could Identify Pediatric LRTIs

Lower-respiratory tract infections (LRTIs) are a leading cause of illness and death worldwide, and pneumonia is the leading infectious cause of death in children under five, claiming the lives of over... Read more

Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection

Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more

Pathology

view channel

Genetics and AI Improve Diagnosis of Aortic Stenosis

Aortic stenosis is a progressive narrowing of the aortic valve that restricts blood flow from the heart and can be fatal if left untreated. There are currently no medical therapies that can prevent or... Read more

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more

Image: Flowchart representing sample collections and small EV isolations from tissue, saliva, and plasma of HNC patients (A Jangholi et al., VIEW (2025). DOI: https://doi.org/10.1002/VIW.20250081)

Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer

Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more

Technology

view channel

Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging

Detecting cancer early and tracking how it responds to treatment remains a major challenge, particularly when cancer cells are present in extremely low numbers in the bloodstream. Circulating tumor cells... Read more

AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features

Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more

Image: The GlioExoChip chip provides a quick and minimally invasive way to monitor glioblastoma treatment response (Photo courtesy of University of Michigan)

Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer

Glioblastoma is one of the most aggressive and fatal brain cancers, with most patients surviving less than two years after diagnosis. Treatment is particularly challenging because the tumor infiltrates... Read more

Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that is notoriously difficult to diagnose in its early stages. Early symptoms often overlap with other neurological... Read more

Industry

view channel

BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry

BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more

Abbott Acquires Cancer-Screening Company Exact Sciences

Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more

$Image: Freenome will evaluate Roche\'s forthcoming SBX technology for future development applications (Photo courtesy of Roche)$

Roche and Freenome Collaborate to Develop Cancer Screening Tests

Roche (Basel, Switzerland) and Freenome (Brisbane, CA, USA have entered into a strategic collaboration to commercialize Freenome's cancer screening technology in international markets.... Read more

Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) has formed a new artificial intelligence (AI) business unit to integrate the company's existing and planned AI applications into its Co-Dx Primer Ai platform.... Read more